1. Fulminant Rhizomucor pusillus mucormycosis during anti-leukemic treatment with blinatumomab in a child: A case report and review of the literature
- Author
-
Leticia Quintanilla-Martinez, Michaela Döring, Matthias Pfeiffer, Rupert Handgretinger, Peter Lang, Karin Melanie Cabanillas Stanchi, Ilias Tsiflikas, G. Wiegand, Martin Ebinger, Susanne Haen, Anna Riecker, and Sarah Schober
- Subjects
0301 basic medicine ,Medicine (General) ,Lymphatic leukemia ,Pathology ,medicine.medical_specialty ,QH301-705.5 ,Fulminant ,Pediatric patients ,030106 microbiology ,030231 tropical medicine ,Ischemia ,Infarction ,Case Report ,Microbiology ,Rhizomucor pusillus ,03 medical and health sciences ,R5-920 ,0302 clinical medicine ,medicine ,Mucormycosis ,Biology (General) ,Acute lymphoblastic leukemia relapse ,biology ,business.industry ,medicine.disease ,biology.organism_classification ,Infectious Diseases ,Allogeneic hematopoietic stem cell transplantation ,Blinatumomab ,business ,Cerebral herniation ,medicine.drug - Abstract
This is the first published case report of a child with acute lymphatic leukemia developing a fatal mucormycosis during blinatumomab treatment. The patient showed multiple, systemic thromboembolic lesions with ischemia, bleeding and infarction in almost all organs. The child succumbed to increased brain pressure resulting in cerebral herniation. This case particularly illustrates the fulminant progression and huge challenges of diagnosing and treating mucormycosis in children with hemato-oncological diseases during treatment with targeted therapeutic antibodies (blinatumomab).
- Published
- 2021